

Aqua Bio Technology ASA: Preliminary results of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN

Reference is made to the stock exchange announcement by Aqua Bio Technology ASA ("ABTEC" or the "Company") on 12 March 2026 regarding the start of the subscription period in a subsequent offering of up to 800,000 new shares (the "Offer Shares"), each at a subscription price of NOK 5.00 (the "Subsequent Offering").

The Subscription Period expired yesterday, 19 March 2026, at 16:30 hours (CET). The Company has been informed by our settlement agent that at the end of the Subscription Period, and based on a preliminary count, valid subscriptions had been received for a total of 388,240 Offer Shares.

The final result of the Subsequent Offering is expected to be announced by the Company on or about 23 March 2026. Investors that are allocated Offer Shares can access information on the number of Offer Shares allocated through VPS on or about 23 March 2026. Further announcements in respect of the Subsequent Offering and the Offer Shares will be made in due course.

The due date for payment of the Offer Shares is on 25 March 2026. Subject to due payment of the Offer Shares by the subscribers, the share capital increase relating to the Subsequent Offering will be registered with the Norwegian Register of Business Enterprises, and the Offer Shares will thereafter be delivered to the VPS accounts of the allocated subscribers on or about 8 April 2026. The Offer Shares will be delivered as listed and tradable shares. First day of trading of the Offer Shares on Euronext Expand is expected on or about 8 April 2026. A separate announcement will be made when the share capital increase has been registered.

IMPORTANT INFORMATION

This announcement is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. Copies of this announcement may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful absent registration, or an exemption from registration or qualification under the securities laws of any jurisdiction.

This document is not for publication or distribution in, directly or indirectly, Australia, Canada, Japan, Hong Kong, South Africa or the United States or any other jurisdiction in which such release,

publication or distribution would be unlawful, and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States or to publications with a general circulation in the United States of America.

This announcement is not an offer for sale of securities in the United States. Securities may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Company does not intend to register any part of the offering in the United States or to conduct a public offering in the United States of the shares to which this document relates. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company.

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

The Company expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise.

Contacts

Kristian Flaten

CEO & CFO

Aqua Bio Technology ASA

Phone: +47 9509 2322

Email: kf@aquabiotech.no

About Us

Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in skincare and nonfood. The group has distribution towards B2C and B2B, and offers freight, customs, and logistics services. The group also develops sustainable biotechnology for use in skincare products. Aqua Bio Technology is listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-20 15:20 CET.